Literature DB >> 7897205

Novel in vitro model for high-rate IgA class switching.

T M McIntyre1, M R Kehry, C M Snapper.   

Abstract

The parameters necessary for induction of high-rate IgA class switching are unknown. Thus, although TGF-beta is switch factor for the IgA class, the percentage of membrane (m)IgA+ cells generated in vitro in response to TGF-beta and various individual modes of B cell activation is limited to 1 to 2% of the total B cell population, a percentage far below that observed within Peyer's patches. In this report we determined a set of parameters that act synergistically to generate up to 15 to 20% mIgA+ cells in vitro. A dual mode of B cell activation is required whereby signaling through CD40 or in response to LPS stimulation must occur in concert with multivalent Ag receptor crosslinking. A complex cytokine requirement is also revealed in that both IL-4 and IL-5 must be present with TGF-beta for high-rate IgA class switching to occur. By contrast, IFN-gamma, a known antagonist of IL-4, strongly suppresses the induction of mIgA+ cells in response to these stimuli. This novel cellular system should serve as a powerful tool for studying the molecular mechanisms that underly the IgA class switch and may provide insight into the physiologic parameters that induce it.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7897205

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

Review 1.  Divide and conquer: the importance of cell division in regulating B-cell responses.

Authors:  Stuart G Tangye; Philip D Hodgkin
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

2.  Evolution of antibody class switching: identification and transcriptional control of an Inu exon in the duck (Anas platyrhynchos).

Authors:  Mats L Lundqvist; Bryan R McElveen; Darlene L Middleton; Robert Chapman; Gregory W Warr
Journal:  Dev Comp Immunol       Date:  2005-06-20       Impact factor: 3.636

Review 3.  From the diet to the nucleus: vitamin A and TGF-beta join efforts at the mucosal interface of the intestine.

Authors:  Daniel Mucida; Yunji Park; Hilde Cheroutre
Journal:  Semin Immunol       Date:  2008-09-21       Impact factor: 11.130

Review 4.  The regulation of IgA class switching.

Authors:  Andrea Cerutti
Journal:  Nat Rev Immunol       Date:  2008-06       Impact factor: 53.106

5.  CD40 engagement triggers switching to IgA1 and IgA2 in human B cells through induction of endogenous TGF-beta: evidence for TGF-beta but not IL-10-dependent direct S mu-->S alpha and sequential S mu-->S gamma, S gamma-->S alpha DNA recombination.

Authors:  H Zan; A Cerutti; P Dramitinos; A Schaffer; P Casali
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

6.  Mechanisms for induction of acquired host immunity by neutrophil peptide defensins.

Authors:  J W Lillard; P N Boyaka; O Chertov; J J Oppenheim; J R McGhee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

7.  Class switch recombination in selective IgA-deficient subjects.

Authors:  L Hummelshoj; L P Ryder; L K Nielsen; C H Nielsen; L K Poulsen
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

8.  Mutations occur in the Ig Smu region but rarely in Sgamma regions prior to class switch recombination.

Authors:  Carol E Schrader; Sean P Bradley; Joycelyn Vardo; Sofia N Mochegova; Erin Flanagan; Janet Stavnezer
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

9.  Dual effect of neutrophils on pIgR/secretory component in human bronchial epithelial cells: role of TGF-beta.

Authors:  Céline Ratajczak; Amélie Guisset; Bruno Detry; Yves Sibille; Charles Pilette
Journal:  J Biomed Biotechnol       Date:  2010-07-08

10.  Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis.

Authors:  Terry Guthrie; Simon Y C Wong; Bin Liang; Lisa Hyland; Sam Hou; E Arne Høiby; Svein Rune Andersen
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.